Dr Chrysi Sergaki
Dr Chrysi Sergaki is the Microbiome Group Leader at MHRA, under Diagnostics R&D, Science, Research and Innovation. At MHRA she is leading the Microbiome Standardisation Program, with 18 World Health Organization (WHO) endorsed projects to develop International Reference Reagents for the microbiome field as well as research projects investigating the role of the microbiome in health and disease through collaborations with NHS, Kings College University, the Francis Crick Institute, Liverpool University and Warwick University Hospital. Chrysi has led the establishment of the 1st WHO International DNA Reference Reagents for microbiome analysis, by leading and coordinating a large, international collaborative study. Further to the scientific work, Chrysi has secured funding from BEIS, via the Regulators’ Pioneer Fund, to develop microbiome guidelines aiming at facilitating the regulatory process for novel microbiome therapeutics and diagnostics (MHRA to receive nearly £1m BEIS funding to unlock digital, data and scientific regulatory innovation - GOV.UK (www.gov.uk)).
Prior to this, Chrysi has been working at MHRA as scientist since 2019 leading research projects as well as the development of reference reagents for the DNA extraction of microbiome samples and will be evaluated as candidates for the first World Health Organization Whole Cell Reference Reagents for the microbiome. Before joining the MHRA, Chrysi completed her PhD at the University of Warwick, UK, researching microbial interactions in fungi and bacteria and their impact on the host.
Chrysi is a member of expert committees and advisory panels on collaboratives projects, such as the International Human Microbiome Coordination and Support action (IHMCSA) Strategic Steering Committee, the Gut Microbiota for Health Expert panel in the UK, the International Microbiome and Multi’omic Standards Alliance (IMMSA), the Pistoia Alliance and many more. She is very keen on the advancements in the microbiome field and keeping up to date with latest research. If you are interested in microbiome research and its impact, or/and the standardisation of the field, Chrysi would be very interested in hearing from you.
- Sergaki C. et al., Developing whole cell standards for the microbiome field, 2022, Microbiome (Developing whole cell standards for the microbiome field | Microbiome | Full Text (biomedcentral.com))
- Sergaki C. et al., WHO/BS/2022.2416: A WHO collaborative study to evaluate the candidate 1st WHO International Reference Reagents for Gut Microbiome analysis by Next-Generation Sequencing
- Hassall J. and Sergaki C., Microbiome therapies: why we are not there yet, 2022, Prescriber (Microbiome therapies: why we are not there yet - Hassall - 2022 - Prescriber - Wiley Online Library)
- Servetas S.L., Daschner P.J., Guyard C., Thomas V., Affagard H., Sergaki C. , et al., Evolution of FMT – From Early Clinical to Standardized Treatments, 2022, Biologicals (Evolution of FMT – From early clinical to standardized treatments - ScienceDirect)
- Amos G.C.A., Sergaki C., et al., Exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations, 2021, Nature Scientific Reports (Exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations | Scientific Reports)